Cyclerion Therapeutics (NASDAQ:KRSA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Cyclerion Therapeutics (NASDAQ:KRSA) to a sell rating in a research report sent to investors on Saturday,Wall Street Zen reports.

A number of other research analysts also recently issued reports on the company. Stifel Nicolaus began coverage on Cyclerion Therapeutics in a research note on Monday, September 14th. They issued a “buy” rating and a $43.00 price objective for the company. Guggenheim initiated coverage on Cyclerion Therapeutics in a research note on Monday, September 28th. They set a “buy” rating and a $70.00 target price on the stock. Zacks Research raised shares of Cyclerion Therapeutics to a “hold” rating in a report on Wednesday, September 9th. TD Cowen began coverage on shares of Cyclerion Therapeutics in a research report on Monday, September 14th. They set a “buy” rating for the company. Finally, UBS Group began coverage on shares of Cyclerion Therapeutics in a report on Friday, September 11th. They set a “buy” rating and a $55.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $53.00.

Cyclerion Therapeutics Price Performance

Shares of KRSA opened at $30.72 on Friday. The company has a market cap of $20.58 million, a P/E ratio of -2.64 and a beta of 1.72. Cyclerion Therapeutics has a 12 month low of $7.19 and a 12 month high of $59.36.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases with substantial unmet medical needs. The company was established in 2019 as a spinout from Ironwood Pharmaceuticals and built its research portfolio around soluble guanylate cyclase (sGC) stimulation, a mechanism involved in regulating blood flow and cellular signaling.

Cyclerion’s development programs included olinciguat, an investigational therapy studied in sickle cell disease and other vascular conditions; praliciguat, an sGC stimulator evaluated for cardiometabolic and renal diseases; and IW-6463, a central nervous system-penetrant sGC stimulator investigated for neurological disorders.